Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD)

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 4, 2013, Pages 353-358

  Scaglioni, Federica ^a   Marino, Mariano ^a   Ciccia, Stefania ^a   Procaccini, Alessia ^a   Busacchi, M ^a   Loria, Paola ^b   Lonardo, Amedeo ^b   Malavolti, Marcella ^b   Battistini, Nino Carlo ^b   Pellegrini, Massimo ^b   Carubbi, Francesca ^b   Bellentani, Stefano ^a,c  

^a AUSL Modena   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Ramazzini Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FAT; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; PROTEIN; SATURATED FATTY ACID;

ADULT; ARTICLE; BEHAVIOR THERAPY; CALORIC INTAKE; CLINICAL ARTICLE; DIET; DIETARY FIBER; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONALCOHOLIC FATTY LIVER; OPEN STUDY; PHYSICAL ACTIVITY; RESTING ENERGY EXPENDITURE;

COMBINED MODALITY THERAPY; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT CARE TEAM; TIME FACTORS;

EID: 84883556330     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.10.009     Document Type: Article

References (41)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346(16):1221-1231.
2. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37(5):1202-1219.
3. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Järvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Dig Liver Dis 2010, 42:320-330.
4. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363(14):1341-1350.
5. Falck-Ytter Y., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001, 21(1):17-26.
6. Matteoni C.A., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
7. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49(4):608-612.
8. Younossi Z.M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011, 9(6):524-530. e1; quiz e60.
9. Younossi Z.M., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53(6):1874-1882.
10. Pascale A., Pais R., Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010, 19(4):415-423.
11. Ratziu V., et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53(2):372-384.
12. Ratziu V., Caldwell S., Neuschwander-Tetri B.A. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010, 52(6):2206-2215.
13. Bellentani S., et al. Behavior therapy in nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008, 47(2):746-754.
14. Loria P., et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010, 42(4):272-282.
15. Thoma C.D.C., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012, 56:255-266. 10.1016/j.jhep.2011.06.010.
16. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
17. Jakicic J.M., et al. Evaluation of the sensewear proarmband to assess energy expenditure during exercise. Med Sci Sports Exerc 2004, 36(5):897-904.
18. Malavolti M., et al. A new device for measuring resting energy expenditure (REE) in healthy subjects. Nutr Metab Cardiovasc Dis 2007, 17(5):338-343.
19. Wadden T.A., Foster G.D. Behavioral treatment of obesity. Med Clin North Am 2000, 84(2):441-461. vii.
20. Fabricatore A.N. Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference?. J Am Diet Assoc 2007, 107(1):92-99.
21. Prochaska J.O., DiClemente C.C. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983, 51(3):390-395.
22. Kumar R., Rastogi A., Sharma M.K., Bhatia V., Tyagi P., Sharma P., et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2012, [Epub ahead of print] PMID: 22790906.
23. Levy J.C., Matthews D.R., Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21(12):2191-2192.
24. Kanauchi M., et al. Homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index, and oral glucose insulin sensitivity index in nonobese, nondiabetic subjects with high-normal blood pressure. J Clin Endocrinol Metab 2003, 88(7):3444-3446.
25. Mari A., et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 24(3):539-548.
26. Svegliati-Baroni G., et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007, 56(9):1296-1301.
27. Lohman T.G., Roche A.F., Martorell R. Anthropometric Standardization Reference Manual. Human 1988, Human Kinetics Books, Champaign IL.
28. Bedogni G., et al. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010, 10:98.
29. Bedogni G., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006, 6:33.
30. Hamaguchi M., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007, 102(12):2708-2715.
31. Ballestri S., Lonardo A., Romagnoli D., Carulli L., Losi L., Day C.P., et al. Ultrasonographic fatty liver indicator, a novel score whch rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 2012, 32(8):1242-1252.
32. Kakkos S.K., et al. Fatty liver in obesity: relation to Doppler perfusion index measurement of the liver. Scand J Gastroenterol 2000, 35(9):976-980.
33. Glantz S. Primer of Biostatistics. Alternative to analysis of variance and t test based on ranks 1981, MacGraw-Hill, New York, 269-311.
34. Calori G., et al. Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology 2011, 54:145-152. 10.1002/hep.24356.
35. Gastaldelli A., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49(5):1537-1544.
36. Marchesini G., et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005, 28(4):333-339.
37. Fracanzani A.L., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008, 48(3):792-798.
38. Mozaffarian D., et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011, 364(25):2392-2404.
39. Promrat K., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
40. Johnson N.A., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009, 50(4):1105-1112.
41. Frith J., et al. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010, 52(1):112-116.